BioXcel Therapeutics (BTAI) Misses Q4 EPS by 53c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q4 EPS of ($1.95), $0.53 worse than the analyst estimate of ($1.42). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $1.08 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Barclays sees global expansion intact, warns against market complacency
• KKR reports over $900M in Q2 monetization income through June 24
• Acuity Brands (AYI) Tops Q3 EPS by 15c